Xeris Biopharma (XERS) Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Biopharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XERS shares.
View XERS analyst ratings or view top-rated stocks.

3 brokerages have issued 1 year price objectives for Xeris Biopharma's stock. Their XERS share price forecasts range from $4.00 to $6.00. On average, they expect the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 77.3% from the stock's current price.
View analysts price targets for XERS or view top-rated stocks among Wall Street analysts.

Xeris Biopharma's stock was trading at $1.33 on January 1st, 2023. Since then, XERS stock has increased by 112.0% and is now trading at $2.82.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our XERS earnings forecast.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) released its earnings results on Wednesday, March, 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.06. The firm earned $33.14 million during the quarter, compared to analyst estimates of $31.04 million. Xeris Biopharma had a negative trailing twelve-month return on equity of 147.04% and a negative net margin of 64.08%.

iShares Neuroscience and Healthcare ETF holds 14,729 shares of XERS stock, representing 0.58% of its portfolio.

Xeris Biopharma updated its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $135.00 million-$165.00 million, compared to the consensus revenue estimate of $146.90 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Biopharma investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Miragen Therapeutics (MGEN), Novan (NOVN), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), Cogent Biosciences (UMRX) and Organigram (OGI).

(XERS) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.

Xeris Biopharma trades on the NASDAQ under the ticker symbol "XERS."

Xeris Biopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Stonepine Capital Management LLC (6.38%), BlackRock Inc. (6.21%), Geode Capital Management LLC (1.87%), State Street Corp (1.68%), JPMorgan Chase & Co. (0.57%) and Deltec Asset Management LLC (0.46%). Insiders that own company stock include Paul R Edick and Steven Prestrelski.
View institutional ownership trends.

Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XERS stock can currently be purchased for approximately $2.82.

Xeris Biopharma (NASDAQ:XERS) has a market capitalization of $382.19 million and generates $110.25 million in revenue each year. The company earns $-94,660,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis.

The company employs 294 workers across the globe.

Xeris Biopharma's mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The official website for the company is www.xerispharma.com. The company can be reached via phone at (844) 445-5704 or via email at ir@xerispharma.com.